Policy & Regulation
GlaxoSmithKline's Nucala succeeds in phase three hypereosinophilic syndrome study
15 November 2019 -

United Kingdom-based GlaxoSmithKline's respiratory drug Nucala (mepolizumab) has succeeded in decreasing flares in patients with hypereosinophilic syndrome in a phase three study, it was reported yesterday.

The late-stage study assessed subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES, an illness that causes patients to have a persistent and notable overproduction of eosinophils.

The HES trial met its primary endpoint of delivering a statistically significant result with 50% less patients experiencing a hypereosinophilic flare in the mepolizumab arm, compared to placebo. The product was assessed for its efficacy and safety in combination with standard of care treatment over the 32-week study period. The firm stated that the late-stage trial's secondary endpoints were also significant statistically, while supporting the primary endpoint.